HRSA Warns J&J About “Unapproved” Rebate Model for 340B Drug Discounts
- September 20, 2024
The Health Resources and Services Administration (HRSA) told Johnson & Johnson (J&J) that it could face civil monetary penalties or even termination of its pharmaceutical pricing agreement if the company moves forward with a new rebate-model policy for obtaining discounts on the company’s two drugs—Stelara and Xarelto—under the 340B program.
ARTICLE TAGS
You must be logged in to access this content.